文献速递皮肤肿瘤

显微手术对比常规切除降低基底细胞癌与鳞状细胞癌复发率的系统综述与荟萃分析

Efficacy of micrographic surgery versus conventional excision in reducing recurrence for basal cell carcinoma and squamous cell carcinoma: A systematic review and meta-analysis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-12-20

MS组总体复发率为3.1%(95%CI 2.0%-4.7%),CS组为5.3%(95%CI 2.9%-9.3%),合并相对风险(RR)为0.48(95%CI 0.36-0.63),绝对风险差(RD)为2.9%(95%CI 1.0%-4.9%;NNT=35)。基于2项RCT为中等证据、15项队列研究为低证据,MS在降低BCC和原发肿瘤复发方面优于CS。

要点

  • MS组总体复发率3.1%,CS组5.3%,合并RR为0.48(95%CI 0.36-0.63)。
  • BCC亚组RR为0.37(95%CI 0.25-0.54),RD为3.7%(95%CI 0.8%-6.5%;NNT=28)。
  • SCC亚组RR为0.57(95%CI 0.29-1.13),RD为1.9%(95%CI 0.8%-4.7%;NNT=53)。

核心结论

  • 基于2项RCT为中等证据、15项队列研究为低证据,MS在降低BCC和原发肿瘤复发方面优于CS。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、LILACS、Embase、Scopus、Web of Science、CINHAL和Cochrane截至2023年5月。
  • 纳入2项随机临床试验和15项队列研究,共涉及接受MS或CS的BCC或SCC患者。
  • 采用Cochrane推荐工具评估偏倚风险,采用GRADE方法评估证据确定性,使用随机效应模型计算相对风险(RR)和绝对风险差(RD)。

主要发现

  • MS组3050个肿瘤中82例复发,总体复发率3.1%(95%CI 2.0%-4.7%);CS组3453个肿瘤中209例复发,复发率5.3%(95%CI 2.9%-9.3%)。
  • 合并RR为0.48(95%CI 0.36-0.63),无 heterogeneity 也无发表偏倚证据(p > 0.3)。
  • RD为2.9%(95%CI 1.0%-4.9%;NNT=35)。
  • BCC亚组RR为0.37(95%CI 0.25-0.54),RD为3.7%(95%CI 0.8%-6.5%;NNT=28);SCC亚组RR为0.57(95%CI 0.29-1.13),RD为1.9%(95%CI 0.8%-4.7%;NNT=53)。
  • 原发肿瘤RR为0.39(95%CI 0.28-0.54),复发肿瘤RR为0.67(95%CI 0.30-1.50)。

关键数值与推荐

  • MS组总体复发率3.1%(95%CI 2.0%-4.7%),CS组5.3%(95%CI 2.9%-9.3%)。
  • 合并RR 0.48(95%CI 0.36-0.63),RD 2.9%(95%CI 1.0%-4.9%;NNT=35)。
  • BCC亚组RR 0.37(95%CI 0.25-0.54),RD 3.7%(95%CI 0.8%-6.5%;NNT=28)。
  • SCC亚组RR 0.57(95%CI 0.29-1.13),RD 1.9%(95%CI 0.8%-4.7%;NNT=53)。
  • 原发肿瘤RR 0.39(95%CI 0.28-0.54),复发肿瘤RR 0.67(95%CI 0.30-1.50)。

临床怎么用

  • 对于BCC和原发肿瘤,MS在降低复发方面优于CS,可优先考虑用于高风险患者。
  • SCC亚组RR的95%CI跨越1,MS的优势证据不充分,需个体化决策。
  • 需制定方案以在不同临床场景中最大化每种方法的成本效益。

局限性

  • 仅2项RCT,多数为队列研究,证据确定性分别为中等和低。
  • SCC亚组和复发肿瘤亚组的RR置信区间较宽,结果不确定性大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The standard of care for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) involves excision by conventional surgery (CS) with a predefined safety margin of resection or micrographic surgery (MS) with microscopic margin control. Previous studies have reported the superiority of MS in reducing recurrences for high-risk BCC and SCC. This systematic review aimed to assess MS and CS recurrence rates by including randomized clinical trials (RCTs) and cohort studies. A systematic review and meta-analysis were conducted for related studies in PubMed, LILACS, Embase, Scopus, Web of Science, CINHAL and Cochrane until May 2023. RCTs and cohorts involving patients with BCC or SCC submitted to MS and CS were included. Risk of bias assessment followed Cochrane-recommended tools for RCTs and cohorts, and certainty of evidence followed the GRADE approach. Pooled estimates were used to determine the relative risk (RR) and absolute risk difference (RD) using a random-effects model. Seventeen studies were included, two RCTs and fifteen cohorts. There were 82 recurrences in 3050 tumours submitted to MS, with an overall recurrence rate of 3.1% (95% CI 2.0%-4.7%). For CS, there were 209 recurrences in 3453 tumours, with a recurrence rate of 5.3% (95% CI 2.9%-9.3%). The combined estimate of RR was 0.48 (95% CI 0.36-0.63), without heterogeneity nor evidence of publication bias (p > 0.3). The RD resulted in 2.9% (95% CI 1.0%-4.9%; NNT = 35). Regarding subgroup analysis, the RR for BBC was 0.37 (95% CI 0.25-0.54), and RD was 3.7% (95% CI 0.8%-6.5%; NNT = 28). For SCC, RR was 0.57 (95% CI 0.29-1.13), and RD was 1.9% (95% CI 0.8%-4.7%; NNT = 53). Among primary tumours, RR was 0.39 (95% CI 0.28-0.54), and for recurrent tumours was 0.67 (95% CI 0.30-1.50). There is moderate evidence based on two RCTs, and low evidence based on 15 cohort studies that MS is superior to CS in reducing recurrences of BCCs and primary tumours. The development of protocols that maximize the cost-effectiveness of each method in different clinical scenarios is paramount.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Lacerda PN, Lange EP, Luna NM, et al. Efficacy of micrographic surgery versus conventional excision in reducing recurrence for basal cell carcinoma and squamous cell carcinoma: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2023. PMID: 38116955. doi:10.1111/jdv.19743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。